Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAYA2
2025-521941-25-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in colorectal cancer (CRC) comparing Temozolomide + capecitabine (TemCap) with Temozolomide + capecitabine + ipilimumab + nivolumab (2 arms). Primary endpoint: Disease control rate at week 16 on TemCap. Planned start Sep 2025; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-521941-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521941-25-00.